Ronald M. Evans,Michael Downes,Annette Atkins,Ruth T. Yu,Sihao Liu
申请号：
US16419929
公开号：
US20190276510A1
申请日:
2019.05.22
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present disclosure provides FGF1 mutant proteins, which include an N-terminal deletion, point mutation(s), or combinations thereof, as well as FGF1-vagus targeting chimeric proteins which include an FGF1 portion (e.g., native FGF1 or mutant FGF1) and a portion that targets the chimera to the vagus nerve (e.g., GLP or exendin-4). Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. The disclosed FGF1 mutants and FGF1-vagus targeting chimeric proteins can reduce blood glucose in a mammal, and in some examples are used to treat a metabolic disorder.
